Recombinant Human T-cell surface protein tactile (CD96)

What is the molecular structure and classification of CD96?

CD96, also known as Tactile (T cell activation, increased late expression), is a member of the immunoglobulin gene superfamily. Its structure includes three Ig domains, a long serine/threonine/proline-rich region characteristic of extensive O-glycosylation, a transmembrane domain, and a 45-residue cytoplasmic domain. The protein shows structural similarity to Drosophila amalgam, melanoma antigen MUC-18, carcinoembryonic antigen family members, poliovirus receptor, and neural cell adhesion molecules .

What is the normal expression pattern of CD96 in hematopoietic cells?

CD96 is expressed on normal T cell lines and clones, as well as some transformed T cell lines. In peripheral T cells, CD96 is expressed at low levels but becomes strongly upregulated following activation, with peak expression occurring 6-9 days post-activation. Additionally, NK cells upregulate CD96 when activated in allogeneic cultures. CD96 is absent on peripheral B cells but can be detected at very low levels on activated B cells . In normal hematopoietic stem cell-enriched populations, CD96 expression is limited to only 4.9 ± 1.6% of cells .

How is CD96 functionally involved in immune regulation?

CD96 functions as an immune checkpoint molecule within the CD226 axis, which is crucial for NK and T cell biology and cancer immune surveillance. Mechanistically, CD96 competes with the costimulatory receptor CD226 for binding to CD155 and CD112 ligands, thereby suppressing immune activation. This competition creates a balance between activating and inhibitory signals in T cells and NK cells. Evidence suggests CD96 plays a role in adhesive interactions of activated lymphocytes during the late phase of immune responses .

How is CD96 expression altered in hematological malignancies?

In acute myeloid leukemia (AML), CD96 is selectively expressed in leukemic stem cells (LSCs). Studies have shown that in 65.5% (19/29) of primary human AML samples, CD96 was expressed in the CD34+CD38- fraction, which is enriched for LSC activity. Importantly, only CD96+ AML cells, not CD96- cells, demonstrated the ability to engraft immunodeficient mice, confirming that CD96 marks the LSC population. This differential expression between normal HSCs and AML-LSCs makes CD96 a potential LSC-specific therapeutic target that could eliminate leukemic stem cells while sparing normal hematopoietic stem cells .

How does CD96 expression correlate with immune infiltration in the tumor microenvironment?

CD96 expression levels correlate with immune cell infiltration patterns across multiple cancer types. Comprehensive analysis using databases such as TIMER2.0 has demonstrated that CD96 expression reflects T cell and NK cell presence within tumors. When comparing tumor tissues from TCGA database with normal tissues from GTEx database, CD96 was differentially expressed in most cancers, with significant increases observed in numerous cancer types including adrenocortical carcinoma, breast cancer, endocervical adenocarcinoma, and head and neck squamous cell carcinoma . This correlation suggests CD96 may serve as a biomarker for immunologically "hot" tumors and influence the efficacy of immunotherapeutic approaches.

What techniques are optimal for detecting and quantifying CD96 expression?

Several complementary techniques have proven effective for CD96 detection and quantification:

For robust results, combining multiple detection methods is recommended to validate findings.

What are the key considerations in producing recombinant CD96 protein for research applications?

While specific production protocols are not detailed in the search results, the following considerations are important based on CD96's molecular characteristics:

• Expression System Selection: Given CD96's complex structure with three Ig domains and extensive O-glycosylation, mammalian expression systems (e.g., HEK293 or CHO cells) would be optimal to maintain proper folding and post-translational modifications.

• Purification Strategy: Affinity chromatography using anti-CD96 antibodies or tag-based systems would facilitate specific purification.

• Structural Validation: SDS-PAGE analysis should reveal bands of approximately 160 kDa when reduced and bands of 240, 180, and 160 kDa when non-reduced, consistent with the native CD96 protein .

• Functional Validation: Binding assays confirming interaction with CD155 and other physiological partners are essential to ensure the recombinant protein maintains native functionality.

How should researchers approach CD96 transcriptional analysis in complex samples?

For transcriptional analysis of CD96:

• RNA Isolation Protocol: Using specialized kits (e.g., Qiagen "miRNeasy mini-Kit") after tissue disruption with instruments like Precellys®, followed by quality assessment using spectrophotometric methods .

• Reverse Transcription: Using high-fidelity cDNA synthesis kits to ensure accurate representation of CD96 transcripts .

• Primer Design: CD96-specific primers should be 20-23 bp in length, generating amplicons of 91-152 bp for optimal qPCR performance .

• Data Analysis: Employ the ΔCT method using GAPDH or other validated housekeeping genes as internal controls, and calculate fold changes using the 2^(-ΔΔCT) formula .

• Statistical Validation: Use nonparametric tests such as Mann-Whitney U to determine significant differences in expression levels between experimental groups .

What is the rationale and current status of CD96-targeted cancer immunotherapies?

The therapeutic potential of targeting CD96 stems from its role as an immune checkpoint molecule that suppresses immune activation. Inhibition or deletion of CD96 has demonstrated antitumor activity in preclinical models, both as monotherapy and in combination with PD-1 inhibition .

GSK6097608, a first-in-class monoclonal antibody that blocks CD96, enhances CD155-CD226 NK/T-cell activation pathways. This agent is currently being investigated in a phase 1, dose-escalation trial (NCT04446351) for patients with locally advanced, recurrent, or metastatic solid malignancies that have progressed after standard therapy. The trial design includes GSK6097608 as monotherapy and in combination with the anti-PD-1 antibody dostarlimab, with primary endpoints focused on safety (dose-limiting toxicities and adverse events) .

What considerations are important when developing CD96-targeted therapies?

Key considerations include:

• Target Specificity: Development of CD96 antibodies that can induce specific cytotoxic mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC), augmented macrophage phagocytosis, or complement-dependent cytotoxicity .

• Off-Target Effects: Recognition that CD96 is expressed on T cells, NK cells, histiocytes, and some non-hematopoietic cells, necessitating careful evaluation of potential adverse effects .

• Patient Selection: Given the variable prognostic impact of CD96 across cancer types, identification of biomarkers for patient stratification is crucial .

• Combination Strategies: Exploration of synergistic combinations with other immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, based on preclinical evidence of enhanced efficacy .

How might CD96 expression be used for patient stratification in clinical trials?

CD96 expression patterns could inform patient stratification strategies:

• In Hematological Malignancies: In AML, quantification of CD96+ LSCs could identify patients with higher LSC burden who might benefit more from CD96-targeted therapies .

• In Solid Tumors: Given the varying prognostic implications of CD96 across cancer types, expression levels could identify subgroups more likely to respond to specific therapeutic approaches .

• Immune Context Assessment: Analyzing CD96 in conjunction with other immune markers (PD-1, PD-L1, CD68, CD163) could provide a more comprehensive immune profile for predicting response to immunotherapy .

How should researchers address discrepancies in CD96 expression data across different platforms?

To address data inconsistencies:

What are the critical controls for CD96 expression studies?

Essential controls include:

• Internal Reference Genes: GAPDH has been validated for normalizing CD96 expression in RT-qPCR studies .

• Tissue-Specific Controls: Include matched normal tissues when analyzing tumor samples .

• Cell Line Controls: Use cell lines with known CD96 expression levels (T cell lines are typically CD96-positive, while most non-immune cell lines are negative) .

• Antibody Validation: Confirm antibody specificity using positive and negative control samples or knockdown/knockout approaches.

• Technical Replicates: Include multiple ROIs (typically 3 or more) when performing IHC analysis to account for tissue heterogeneity .